These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 30746719)
41. Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease. Kazemi K; Geramizadeh B; Nikeghbalian S; Salahi H; Bahador A; Reza Nejatollahi SM; Dehghani SM; Dehghani M; Kakaei F; Malek-Hosseini SA Exp Clin Transplant; 2008 Dec; 6(4):261-3. PubMed ID: 19338486 [TBL] [Abstract][Full Text] [Related]
42. Triethylene-tetramine (trien) therapy for Wilson's disease. Saito H; Watanabe K; Sahara M; Mochizuki R; Edo K; Ohyama Y Tohoku J Exp Med; 1991 May; 164(1):29-35. PubMed ID: 1926144 [TBL] [Abstract][Full Text] [Related]
43. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438 [TBL] [Abstract][Full Text] [Related]
44. [Clinical character and therapeutic effect of late-onset Wilson disease]. Zhang Y; Yang X; Tang X; Luo H; Lei J Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 34(1):40-4. PubMed ID: 19197125 [TBL] [Abstract][Full Text] [Related]
45. Metal element excretion in 24-h urine in patients with Wilson disease under treatment of D-penicillamine. Huang L; Yu X; Zhang J; Liu X; Zhang Y; Jiao X; Yu X Biol Trace Elem Res; 2012 May; 146(2):154-9. PubMed ID: 22076732 [TBL] [Abstract][Full Text] [Related]
46. Role of Oxidative Stress in the Worsening of Neurologic Wilson Disease Following Chelating Therapy. Kalita J; Kumar V; Ranjan A; Misra UK Neuromolecular Med; 2015 Dec; 17(4):364-72. PubMed ID: 26224517 [TBL] [Abstract][Full Text] [Related]
48. The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper. Brewer GJ; Hill G; Prasad A; Dick R Proc Soc Exp Biol Med; 1987 Apr; 184(4):446-55. PubMed ID: 3562454 [TBL] [Abstract][Full Text] [Related]
53. [Late-onset Wilsońs disease]. Campos Franco J; Domínguez Santalla MJ; Tomé Martínez de Rituerto S; Otero Antón E; González Quintela A An Med Interna; 2003 Aug; 20(8):416-8. PubMed ID: 14516263 [TBL] [Abstract][Full Text] [Related]
54. Wilson disease in children: analysis of 57 cases. Manolaki N; Nikolopoulou G; Daikos GL; Panagiotakaki E; Tzetis M; Roma E; Kanavakis E; Syriopoulou VP J Pediatr Gastroenterol Nutr; 2009 Jan; 48(1):72-7. PubMed ID: 19172127 [TBL] [Abstract][Full Text] [Related]
55. D-penicillamine and plasmapheresis in acute liver failure secondary to Wilson's disease. Rodríguez Fariña E; Tremosa Llurba G; Xiol Quingles X; Lores Obradors A; Castellote Alonso J; Gornals Soler JB; López Núñez C Rev Esp Enferm Dig; 2003 Jan; 95(1):60-2, 63-5. PubMed ID: 12760731 [TBL] [Abstract][Full Text] [Related]
56. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. Brewer GJ; Dick RD; Johnson VD; Brunberg JA; Kluin KJ; Fink JK J Lab Clin Med; 1998 Oct; 132(4):264-78. PubMed ID: 9794697 [TBL] [Abstract][Full Text] [Related]
57. Copper distribution among serum proteins in paediatric liver disorders and malignancies. Barrow L; Tanner MS Eur J Clin Invest; 1988 Dec; 18(6):555-60. PubMed ID: 3147183 [TBL] [Abstract][Full Text] [Related]
58. The effect of certain chelating compounds on the urinary excretion of copper by the rat: observations on their clinical significance. Gibbs K; Walshe JM Clin Sci Mol Med; 1977 Oct; 53(4):317-20. PubMed ID: 913055 [TBL] [Abstract][Full Text] [Related]
60. A clinical study of Wilson's disease: The experience of a single Egyptian Paediatric Hepatology Unit. El-Karaksy H; Fahmy M; El-Raziky MS; El-Hawary M; El-Sayed R; El-Koofy N; El-Mougy F; El-Hennawy A; El-Shabrawi M Arab J Gastroenterol; 2011 Sep; 12(3):125-30. PubMed ID: 22055589 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]